Uses for medical devices having a lubricious, nitric oxide-releasing coating

A method of treating the circulatory vasculature of a patient following heart transplantation, comprising:

• providing a medical device configured to be implanted within the circulatory vasculature of a patient proximate to the transplanted heart;
• coating the medical device having a coating comprising:
• nitric oxide associated with and releasable from a polyurea network formed from a reaction on the medical device, the reaction comprising a mixture of:
• (a) a polyisocyanate;
• (b) an amine donor;
• (c) an isocyanatosilane adduct having at least one terminal isocyanate group and at least one hydrolyzable alkoxy group bonded to silicon;
• and optionally
• (d) a polymer selected from the group consisting of a polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, and polyacrylic acid;
• and
• implanting within the circulatory vasculature of a patient proximate to the transplanted heart.

A method of treating vasospasms within the vasculature of a patient, comprising:

• providing a medical device configured to be implanted within the vasculature of a patient;
• coating the medical device having a coating comprising:
• nitric oxide associated with and releasable from a polyurea network formed from a reaction on the medical device, the reaction comprising a mixture of:
• (a) a polyisocyanate;
• (b) an amine donor;
• (c) an isocyanatosilane adduct having at least one terminal isocyanate group and at least one hydrolyzable alkoxy group bonded to silicon;
• and optionally
• (d) a polymer selected from the group consisting of a polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, and polyacrylic acid;
• and
• implanting the coated medical device within the vasculature of a patient.

A device for treating the vasculature of a patient, comprising:

• a medical device configured to be inserted into the vasculature of the patient;
• and
• a coating applied to the medical device, the coating comprising:
• nitric oxide associated with and releasable from a polyurea network formed from a reaction on the medical device, the reaction comprising a mixture of:
• (a) a polyisocyanate;
• (b) an amine donor;
• (c) an isocyanatosilane adduct having at least one terminal isocyanate group and at least one hydrolyzable alkoxy group bonded to silicon;
• and optionally
• (d) a polymer selected from the group consisting of a polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, and polyacrylic acid.